does glp-1 cross the blood brain barrier glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action Brain access of incretins and
Description
[DOI] [PubMed] [Google Scholar] 749.Dossat A.M., Diaz R., Gallo L., Panagos A., Kay K., Williams D.L
GLP-1 Weight Management Progress: Timeline and Expectations GLP-1-based treatments, such as compounded semaglutide, are used as part of supervised wellness programs
6.3 Neurodegenerative disorders Recent research indicates that GLP-1 receptor agonists are potentially advantageous for neurodegenerative disorders (Table 2), especially in light of the recognized association between diabetes and dementia
& Husain, M
